Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer

Abstract:
The Overall Non-Small-Cell Lung Cancer Drug Market Will Expand from $4.2 Billion in 2010 to $5.4 Billion in 2020, According to Findings from Decision Resources

In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer

Burlington, MA | Posted on March 29th, 2012

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, nanoparticle paclitaxel (Celgene's Abraxane) in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) will earn Decision Resources' proprietary clinical gold standard status for first-line advanced squamous non-small-cell lung cancer in 2015, following its launch for the indication in 2012. Owing to its competitive advantages in efficacy, nanoparticle paclitaxel in combination with carboplatin will displace Decision Resources' current proprietary clinical gold standard, gemcitabine (Eli Lilly's Gemzar, generics) plus carboplatin.

Decision Resources' analysis of the non-small-cell lung cancer drug market also finds that surveyed U.S. oncologists and managed care organization (MCO) pharmacy directors agree that increased overall survival is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in first-line advanced squamous non-small-cell lung cancer. Clinical data and interviewed thought leaders indicate that nanoparticle paclitaxel in combination with carboplatin, ipilimumab (Bristol-Myers Squibb's Yervoy) in combination with paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin, and necitumumab (ImClone Systems/Bristol-Myers Squibb) in combination with gemcitabine/cisplatin* have advantages on this attribute over sales-leading gemcitabine/carboplatin.

The findings also reveal that, despite the generic erosion of numerous key agents that treat the disease, the non-small-cell lung cancer drug market will expand from $4.2 billion in 2010 to $5.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, drug sales for metastatic/advanced squamous cell non-small-cell lung cancer, which comprises only a small fraction of the market, will decrease from nearly 17 percent in 2010 to approximately 13 percent in 2020.

"Notably, sales of Eli Lilly's Alimta and Genentech/OSI Pharmaceuticals/Roche/Chugai Pharmaceutical's Tarceva—two branded agents that are prescribed principally to patients with non-squamous cell histology and dominated the non-small-cell lung cancer space in 2010—will weaken from 2015 to 2020," said Decision Resources Analyst Karen Pomeranz, Ph.D.

According to surveyed U.S. oncologists and MCO pharmacy directors, increasing overall survival is one of the greatest unmet needs in first-line advanced squamous non-small-cell lung cancer. Clinical data and interviewed thought leaders indicate that nanoparticle paclitaxel/carboplatin, ipilimumab in combination with paclitaxel/carboplatin, and necitumumab in combination with gemcitabine/cisplatin have demonstrated the potential to partially fulfill this unmet need.

*Cisplatin (Bristol-Myers Squibb's Platinol-AQ/Briplatin, Pfizer's Platosin, OSI Pharmaceuticals/Nippon Kayaku's Randa, generics).

Decision Resources' Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

####

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, please click here

Contacts:
Decision Resources
Christopher Comfort, 781-993-2597

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Switching to spintronics: Berkeley Lab reports on electric field switching of ferromagnetism at room temp December 17th, 2014

ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014

Possible Futures

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Researchers discern the shapes of high-order Brownian motions November 17th, 2014

VDMA Electronics Production Equipment: Growth track for 2014 and 2015 confirmed: Business climate survey shows robust industry sector November 14th, 2014

Open Materials Development Will Be Key for HP's Success in 3D Printing: HP can make a big splash in 3D printing, but it needs to shore up technology claims and avoid the temptation of the razor/razor blade business model in order to flourish November 11th, 2014

Nanomedicine

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Announcements

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Unraveling the light of fireflies December 17th, 2014

Fraud-proof credit card possible because of quantum physics December 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE